Tenderwize
Zurück zur Suche

Open-house biologics rebate agreement for PEG-Epoetin beta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jan 30, 2028 · 521 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-38 - PEG-Epoetin beta

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

For monthly inclusion in pharmacy software, complete documents must reach TK by the 3rd day of the previous month; late...

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Supply of pharmaceutical products for PEG-Epoetin beta under an open-house rebate agreement.
  • Conclusion of rebate contracts with all suitable pharmaceutical manufacturers meeting the stated conditions.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for PEG-Epoetin beta pharmaceutical products in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The contract is non-exclusive, with no individual negotiations, and can be joined at any time during the contract period. The notice states a maximum duration of 24 months from 01.02.2026 to 31.01.2028. No contract value is provided. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the notice says the procurement documents are available online but were not fully analyzed as separate extracted document text is not provided beyond the XML notice.

Risiken

For monthly inclusion in pharmacy software, complete documents must reach TK by the 3rd day of the previous month; late...

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG for the relevant medicinal product.
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house biologics rebate agreement for PEG-Epoetin beta

Open-house supply contract for rebate agreements under § 130c Abs. 1 SGB V for the active substance PEG-Epoetin beta. The lot is nationwide in Germany and is described as non-exclusive, with uniform conditions and no individual negotiations. The extracted XML notice indicates that contracts are opened directly and concluded once the stated conditions are met.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Jan 30, 2028

Vergabedetails

Veröffentlichungsdatum
03 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
804419-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3